Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

Beacon Securities analyst Russell Stanley reiterated a “Buy” rating and maintained his $17.00 target price on FTG ...

FOX Sports NBA analyst Rachel Nichols says she has heard the Miami Heat are Ja Morant's preferred landing spot if the Memphis ...

Recent analyst upgrades have pushed Howmet Aerospace (HWM) into focus after the company raised its financial guidance, ...

Long-term prospects for sector are ‘very promising’, but market in the short term is ‘mainly driven by speculative sentiment’ ...

“Our upgrade is premised on our view that 2026 is poised to be another year of significant positive estimate revisions,” Citi ...

Palantir has been showing strong growth momentum, with Truist maintaining a bullish outlook for potential 2026 upside.

Neogen’s Q4 results were met with a strong positive market reaction, reflecting the company’s return to positive core growth ...

WuXi AppTec highlighted the strength of its integrated CRDMO model and growing exposure to late-stage and commercial assets ...

Rocket Lab shares surge 6% to record high on $816M defense contract. Analyst calls company top SpaceX alternative ahead of ...

Bernstein names aerospace manufacturer top 2026 pick, raises target to $298 on production growth and cash flow projections of ...

Two of Opus's seven gene therapy assets are in clinical trials, with additional programs expected to enter the clinic.